Company Profile: Agile Sciences

CED Life Science Conference 2017 - Lightning Round & Innovation Room                                                  
Sub-sector: Biotech and Pharmaceutical                                                                
Year Founded: 2007

Agile Sciences is developing a more effective therapeutic strategy for treating multidrug resistant (MDR) bacterial infections. The company’s core technology consists of a new class of 2-aminoimidazole (2-AI) small molecules that inhibit bacterial defense mechanisms through a novel non-biocidal mode of action resulting in enhanced antibiotic activity by inhibiting and dispersing bacterial communities, known as biofilms, and restoring antibiotic susceptibility in drug resistant infections. Agile Sciences is targeting three therapeutic areas: 1) treatment of MDR bacterial infections; 2) treatment of lung infections in cystic fibrosis (CF) patients; and 3) treatment of chronic wound infections.

Malcolm Thomas, CEO
Dr. John Cavanagh, Founder and CSO
Dr. Christian Melander, Founder and CRO


  • Funding: $14.6MM from grants and contracts
  • Seven new issued patents
  • Received $3.7MM small business contract from NIH
  • Received four small business grants totaling $4.5MM from NIH
  • Received $50k of matching funds from NC One program
  • Successfully advanced three programs into efficacy testing in relevant animal model
  • Agile Sciences has been awarded >$12.8M in small business grants and contracts from NIH, Cystic Fibrosis Foundation, and Bay Area Lyme Foundation
  • Featured in numerous conferences including BIO International Convention, NC Ag Biotech Entrepreneurial Showcase, Antimicrobial Resistance
  • Also featured at several RESI conferences and made presentations or chaired a panel at Regulatory conferences in Cary (2015/2016)

CED, NC State Office of Technology Transfer, North Carolina Biotechnology Center

Malcolm Thomas
Raleigh, NC

Learn more about the CED Life Science Conference.